A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer

Oncology

Volumn 56, Issue 4, 1999, Pages 291-296

  Polyzos, Aristidis ^a   Tsavaris, N ^a   Kosmas, C ^a   Giannikos, L ^a   Katsikas, M ^a   Kalahanis, N ^a   Karatzas, G ^a   Christodoulou, K ^a   Giannakopoulos, K ^a   Stamatiadis, D ^a   Katsilambros, N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Carboplatin; Cyclophosphamide; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFECTIOUS COMPLICATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032967753     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011980     Document Type: Article

References (26)

1. Neijt JP, ten Bokkel-Huinink WW, van der Burg MEL, et al: Long-term survival in ovarian cancer. Eur J Cancer 1991;27:1367-3172.
2. Howell SB, Zimm S, Markman M, et al: Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987;5:1607-1612.
3. Kirmani S, Lucas WE, Kim S, et al: A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J Clin Oncol 1991;9:649-657.
4. Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, et al: Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol 1989;7:1327-1332.
5. Hacker NF, Berek JS, Pretorius RG, Zuckerman J, Eisenkop S, Lagasse LD: Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer. Obstet Gynecol 1987;70:759-764.
6. Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Almadrones L, et al: Intraperitoneal cisplatin and cytarabine in the treatment of refractory ovarian carcinoma. J Clin Oncol 1991;9:204-210.
7. Piver MS, Lele SB, Marchetti DL, Baker TR, Emrich LJ, Hartman AB: Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol 1988;6: 1679-1684.
8. Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr, Rubin S, et al: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9:1801-1805.
9. Howell SB, Zimm S, Markman M, Abramson IS, Cleary S, Lucas WE, et al: Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987;5:1607-1612.
10. Howell SB, Kirmani S, Lucas WE, Zimm S, Goel R, Kim S, et al: A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer. J Clin Oncol 1990;8:137-145.
11. Alberts DS, Liu PY, Hanningan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335: 1950-1955.
12. Speyer JL, Beller U, Colombo N, Sorich J, Wernz JC, Hochster H, et al: Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol 1990;8:1335-1341.
13. Pfeiffer P, Bennedaek O, Bertelsen K: Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 1990;36:306-311.
14. Polyzos A, Kalahanis N, Xefteri E, et al: Intraperitoneal carboplatin and 5-fluorouracil with systemic chemotherapy as a first-line treatment for bulky disease and in recurrent ovarian carcinoma. Proc Am Assoc Cancer Res 1990;31: 1120.
15. WHO Handbook for Reporting Results of Cancer Treatment. Offset publ. No 48. The Hague, Nijhoff, 1979.
16. Kaplan EL, Meir P: Non-parametric estimation for incomplete observations. J Am Statist Assoc 1958;53:457-481.
17. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1-9.
18. Alberts DS, Young L, Mason N, Salmon SE: In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985;12(suppl4):38-42.
19. Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW, McVie JG: Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989;49:3380-3384.
20. Swenerton KD, Pater JL for the Ovarian Cancer Subcommittee: Carboplatin in the treatment of carcinoma of the ovary: The National Cancer Institute of Canada experience. Semin Oncol 1992;19(suppl2):114-119.
21. Piccart MJ, Speyer JL, Markman M, et al: Intraperitoneal chemotherapy: Technical experience at five institutions. Semin Oncol 1985; 12(suppl4):90-96.
22. Markman M: Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 1986;13: 219-242.
23. Chambers SK, Chambers JT, Davis CA, et al: Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. J Clin Oncol 1977; 15:1945-1952.
24. Los G, Verdegaal EME, Mutsaers PHA, McVie JG: Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991;28:159-165.
25. Markman M, Reichman B, Hakes T, et al: Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarianc cancer. Gynecol Oncol 1993; 50:100-104.
26. Tossefi F, Rocco M, Fulco RA, et al: Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin. Anticancer Res 1988;8:381-386.